Advances in Therapeutic Strategies for Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 510
Special Issue Editors
Interests: cancer
Interests: robotic and laparoscopic surgery; urinary calculus; oncological urology; andrology; incontinence and genitourinary prolapse; phimosis and circumcision
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Advances in therapeutic strategies for prostate cancer have seen significant progress in recent years. These advancements encompass various approaches, including:
- Precision Medicine: Tailoring treatments based on the patient's genetic profile has become increasingly common. This allows for more targeted therapies and reduced side effects.
- Immunotherapy: Immune checkpoint inhibitors and other immunotherapeutic approaches have shown promise in boosting the body's immune response to prostate cancer cells.
- Radiation Therapy: Techniques such as stereotactic body radiation therapy (SBRT) and proton therapy offer more precise and effective ways to target prostate tumors while minimizing damage to surrounding tissues.
- Hormone Therapy: New drugs and combinations have been developed to improve the management of advanced prostate cancer by blocking or inhibiting the hormones that fuel tumor growth.
- Minimally Invasive Surgery: Robotic-assisted surgery has enhanced the precision and recovery time for patients undergoing prostatectomies.
- Liquid Biopsies: Liquid biopsy techniques have emerged to detect prostate cancer at an earlier stage and monitor its progression more effectively.
- Targeted Therapies: Drugs that specifically target key molecular pathways involved in prostate cancer growth have been developed, offering new treatment options.
These advances collectively represent a more personalized and effective approach to prostate cancer treatment, providing hope for improved outcomes and quality of life for patients. Ongoing research and clinical trials continue to drive innovation in this field.
Dr. Angelo Naselli
Dr. Giacomo Maria Pirola
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- radiation therapy
- hormone therapy
- targeted therapies
